Sanofi licenses diabetic foot ulcer candidate from Toronto hospital
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis and Toronto-based Sunnybrook Health Services Center have entered into a research agreement and licensing option for an investigational angiogenic compound, vasculotide, to treat chronic wounds, including neuropathic diabetic foot ulcers. Clinical trials with the candidate have not yet begun.